Genetic Technologies grants third license to Monsanto
Genetic Technologies Limited announced that it has granted a third license to Monsanto Company. Genetic Technologies had previously granted a non-exclusive license to the GTG non-coding patents to Monsanto in 2007 for all applications in plants and plant products. Soon after, GTG also granted Monsanto a further non-exclusive license for applications in swine. The current license now grants Monsanto similar rights for cattle. The commercial terms of this further license are covered by formal confidentiality provisions within the relevant Settlement and License Agreement and therefore cannot be disclosed.
This new license follows recent discussions with Monsanto, further to the patent infringement law suit filed by Genetic Technologies in the Western District of Wisconsin earlier this year.
Genetic Technologies is also now engaged in discussions with other parties pertaining to this law suit and further details will be released to the Market as additional license agreements are duly executed. Genetic Technologies is also engaged in a number of licensing negotiations separate to this law suit and details of relevant outcomes from these additional activities will similarly be released to the Market, as appropriate.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Evolva receives clearance to move EV-077 into Phase IIa

InvIOs raises €8.2 million in a Series A to finance pipeline progress in immuno-oncology

Cellular transport routes - Biologists discover new mechanisms of protein transport in plant cells
